Matthew John McCourt

Title: Matthew John McCourt: Innovator in Immuno-Oncology

Introduction

Matthew John McCourt is a prominent inventor based in Cambridge, GB. He has made significant contributions to the field of immuno-oncology, particularly through his innovative work on anti-ICOS antibodies. With a total of 6 patents to his name, McCourt's inventions are paving the way for new therapeutic approaches in cancer treatment.

Latest Patents

Among his latest patents, McCourt has developed anti-ICOS antibodies that bind to the Inducible T cell Co-Stimulator (ICOS). These antibodies have therapeutic applications for modulating the ratio between regulatory T cells and effector T cells, which can stimulate the immune system of patients, including those with cancer. Additionally, he has created methods for producing anti-ICOS antibodies, including species cross-reactive antibodies using transgenic knock-out mice. Another notable invention is a bispecific antibody for ICOS and PD-L1, which is a multispecific antibody in mAb2 format. This antibody comprises an ICOS-binding Fab region and a PD-L1-binding Fcab region, and it is intended for use in immuno-oncology, particularly for treating solid tumors. His combination therapy also includes antibodies targeting other immune checkpoint molecules such as PD-1 and CTLA-4, alongside anti-ICOS and anti-PD-L1.

Career Highlights

Matthew John McCourt has worked with notable companies in the biotechnology sector, including Kymab Limited and MedImmune Limited. His work in these organizations has contributed to advancements in therapeutic antibody development and cancer treatment strategies.

Collaborations

Some of McCourt's notable coworkers include Richard Charles Alfred Sainson and Stephen John Arkinstall. Their collaborative efforts have further enhanced the research and development of innovative therapies in the field.

Conclusion

Matthew John McCourt is a key figure in the development of novel immunotherapies, particularly through his work on anti-ICOS antibodies. His contributions are vital in the ongoing fight against cancer, showcasing the importance of innovation in medical research.